Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology

Derendorf H., Daley-Yates P.T., Pierre L.N., Efthimiou J.

Source: Eur Respir J 2001; 17: 157-158
Journal Issue: January

PDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Derendorf H., Daley-Yates P.T., Pierre L.N., Efthimiou J.. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001; 17: 157-158

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology
Source: Eur Respir J 2001; 18: 246
Year: 2001


Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship
Source: Eur Respir J, 55 (1) 1902193; 10.1183/13993003.02193-2019
Year: 2020



Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma
Source: Eur Respir J 2006; 28: 1042-1050
Year: 2006



Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
Source: Eur Respir Rev, 29 (155) 190151; 10.1183/16000617.0151-2019
Year: 2020



Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Once per day inhaled corticosteroids: a method to improve compliance and asthma control
Source: Eur Respir J 2001; 18: Suppl. 33, 441s
Year: 2001

Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Mechanisms of systemic side effects of inhaled steroids
Source: Eur Respir J 2004; 24: Suppl. 48, 347s
Year: 2004

Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Pharmacokinetic factors affecting airway selectivity of inhaled steroids – role of prodrug conversion and absorption
Source: Eur Respir J 2004; 24: Suppl. 48, 347s
Year: 2004

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006



Systemic activity of two different dry powder combinations of inhaled corticosteroids and long-acting β2-agonists in children with asthma assessed by knemometry
Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy
Year: 2012

Evaluating the effects of inhaled corticosteroid on insulin sensitivity in asthmatic patients
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016


Comparison of long-acting inhaled beta2–agonists plus inhaled steroids versus increasing dose of inhaled steroids on exhaled nitric oxide among asthmatic children poorly controlled
Source: Eur Respir J 2005; 26: Suppl. 49, 617s
Year: 2005

Changes in glucose metabolism during treatment with high doses of inhaled corticosteroids
Source: Eur Respir J 2004; 24: Suppl. 48, 502s
Year: 2004

Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009


Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation
Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2010